

## Supplementary Online Content

Berg M, Welty TE, Gidal BE, et al. Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial. *JAMA Neurol*. Published online June 26, 2017.  
doi:10.1001/jamaneurol.2017.0497

### **eFigure.** EQUIGEN Single-Dose Study Design

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure. EQUIGEN Single-Dose Study Design**

There are 3 equivalent sequences incorporating replication with each of the 3 products studied twice. All 3 products are studied once in the first 3 periods so that average bioequivalence analyses can be performed on participants who only completed the first 3 periods. PK indicates pharmacokinetic; hr, hour; d, day; gLTG1, generic lamotrigine-high; and gLTG2, generic lamotrigine-low.

